Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Neuroendocrine Tumors × tremelimumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Carcinoma, Hepatocellular 22 Carcinoma, Non-Small-Cell Lung 12 Squamous Cell Carcinoma of Head and Neck 10 Urinary Bladder Neoplasms 9 Melanoma 9 Breast Neoplasms 9 Colorectal Neoplasms 8 Lung Neoplasms 6 Cholangiocarcinoma 6 Carcinoma, Renal Cell 6 Biliary Tract Neoplasms 6 Ovarian Neoplasms 5 Liver Neoplasms 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Adenocarcinoma Of Esophagus 5 Uterine Cervical Neoplasms 4 Small Cell Lung Carcinoma 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Mesothelioma, Malignant 4 Head and Neck Neoplasms 4 Stomach Neoplasms 3 Neoplasm Metastasis 3 Mesothelioma 3 Kidney Neoplasms 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Carcinoma, Transitional Cell 3 Vulvar Neoplasms 2 Vaginal Neoplasms 2

Interventions

lutetium Lu 177 dotatate 28 Everolimus 17 Magnetic Resonance Spectroscopy 10 gallium Ga 68 dotatate 9 Temozolomide 9 Capecitabine 9 lanreotide 8 Nivolumab 8 Positron Emission Tomography Computed Tomography 7 177Lu-octreotide, DOTA(0)-Tyr(3)- 7 cabozantinib 6 Somatostatin 6 90Y-octreotide, DOTA-Tyr(3)- 6 3-Iodobenzylguanidine 6 pembrolizumab 5 Octreotide 5 Lutetium-177 5 Ga(III)-DOTATOC 5 Fluorodeoxyglucose F18 5 telotristat ethyl 4 avelumab 4 Carboplatin 4 Bevacizumab 4 Al18F-NOTA-octreotide 4 pasireotide 3 lenvatinib 3 fluorodopa F 18 3 copper dotatate CU-64 3 Surveys and Questionnaires 3 Single Photon Emission Computed Tomography Computed Tomography 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03095274 2025-01-09

DUNE

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed

126 enrolled 18 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡